Transcriptional repression of MHC-I has been observed in a range of cancers, including neuroendocrine tumors such as N-myc-driven neuroblastoma, small-cell lung cancer (SCLC) and Merkel cell carcinoma (MCC), and has recently been identified as a mechanism of resistance to immunotherapy (Bernards et al., 1986, Restifo et al., 1993, Paulson et al., 2018). The gene discussed is MYCN; the disease is Merkel cell skin cancer.